Linked Life Data

15914321

Source:http://linkedlifedata.com/resource/pubmed/id/15914321

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7-8
pubmed:dateCreated
2005-5-25
pubmed:abstractText
We have analyzed the effect of a patented glycoconjugate of natural origin, AM3 (commercially available under the name Inmunoferon) in the expression of iNOS induced by administration of LPS in mice. We have observed that oral treatment with the drug daily for 6 days reduced the levels of expression of iNOS induced by an intravenous pulse of LPS. This effect was significant in the lungs and kidneys, but it was much more marked in the liver. In addition, the levels of nitric oxide in serum were clearly decreased upon treatment with AM3. Together, these results suggest that AM3 modulates the nitric oxide response and points to a possible role for AM3 in the control of the inflammatory response.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1567-5769
pubmed:author
pubmed:issnType
Print
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1165-70
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
AM3 inhibits LPS-induced iNOS expression in mice.
pubmed:affiliation
Unidad de Biología Molecular, Hospital Universitario de la Princesa, U.A.M., Madrid, Spain.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't